126
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection

ORCID Icon, , ORCID Icon, , , , & show all
Pages 5759-5770 | Published online: 16 Sep 2021

References

  • Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B: hepatology, Month 2015. Hepatology. 2016;63(1):261–283. doi:10.1002/hep.28156
  • Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–238. doi:10.2471/BLT.18.219469
  • Xiang Y, Chen P, Xia JR, Zhang LP. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies. Gene Mol Res. 2017;16(1). doi:10.4238/gmr16019102
  • Wang J, Zhou B, Lai Q, et al. Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B e antigen and antibody detection: concurrent circulation of HBeAg and anti-Hbe. J Viral Hepat. 2011;18(9):646–652. doi:10.1111/j.1365-2893.2010.01345.x
  • Lim CK, Tan JTM, Khoo JBS, et al. Correlations of HBV genotypes, mutations affecting HBeAg expression and HBeAg/ anti-HBe status in HBV carriers. Int J Med Sci. 2006;3(1):14–20. doi:10.7150/ijms.3.14
  • Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
  • Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–390. doi:10.1007/s12072-019-09946-3
  • Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
  • Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346
  • World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection; 2015.
  • Blasi A, Calvo A, Prado V, et al. Coagulation failure in patients with acute-on-chronic liver failure and decompensated cirrhosis: beyond the international normalized ratio. Hepatology. 2018;68(6):2325–2337. doi:10.1002/hep.30103
  • Chen J, Duan Z-P, Bai L, et al. [Changing characteristic of blood coagulation factors and their correlation with blood coagulation status in different hepatic diseases]. Zhonghua Gan Zang Bing Za Zhi. 2012;20(3):206–210. doi:10.3760/cma.j.issn.1007-3418.2012.03.014. [ Chinese].
  • Lin B, Ha NB, Liu A, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28(5):855–860. doi:10.1111/jgh.12108
  • Reverberi R, Reverberi L. Factors affecting the antigen-antibody reaction. Blood Transfus. 2007;5(4):227–240. doi:10.2450/2007.0047-07
  • Wiggelinkhuizen J, Sinclair-Smith C, Stannard LM, Smuts H. Hepatitis B virus associated membranous glomerulonephritis. Arch Dis Child. 1983;58(7):488–496. doi:10.1136/adc.58.7.488
  • Liaw Y-F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18(3):246–252. doi:10.1046/j.1440-1746.2003.02976.x
  • Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology. 1983;84(2):216–219. doi:10.1016/S0016-5085(83)80114-0
  • Yoo BC, Park J-W, Kim HJ, Lee DH, Cha YJ, Park SM. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol. 2003;38(1):98–103. doi:10.1016/s0168-8278(02)00349-5
  • Sayed SK, Kobeisy MA. The relationship between core promoter mutation of hepatitis B virus, viral load and hepatitis B e antigen status in chronic hepatitis B patients. Cell Immunol. 2012;276(1–2):35–41. doi:10.1016/j.cellimm.2012.03.003
  • Silva Souza ACD, Souza Marasca GD, Kretzmann-Filho NA, et al. Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil. Braz J Infect Dis. 2017;21(5):525–529. doi:10.1016/j.bjid.2017.05.002
  • Fang Z-L, Sabin CA, Dong B-Q, et al. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J Hepatol. 2009;50(2):273–280. doi:10.1016/j.jhep.2008.09.014
  • Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol. 2000;81(Pt 1):75–83. doi:10.1099/0022-1317-81-1-75
  • Wei F, Zheng Q, Li M, Wu M. The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis. Medicine. 2017;96(19):e6835. doi:10.1097/MD.0000000000006835
  • Chen Y-H, Lu S-N, Wang J-H, Hung C-H, Hu T-H, Chen C-H. Pre-S/surface and core promoter/precore mutations in chronic hepatitis B patients with severe acute exacerbation. Dig Dis Sci. 2019;64(9):2563–2569. doi:10.1007/s10620-019-05571-0
  • Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget. 2016;7(11):12525–12536. doi:10.18632/oncotarget.7123
  • Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Oncol. 2005;34(Suppl 1):S125–S129. doi:10.1016/s1386-6532(05)80021-6